US regulatory status: approved.
pharma · No medical condition. · Generalized Myasthenia Gravis
Anaxis Pharma
Lacuna Pharma Pty Ltd
Anaxis Pharma drug portfolio — 200 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Melbourne, AU HQ
2017 Founded
7 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Melbourne, AU
- Founded
- 2017
- Employees
- 7
- Programs
- 642
- Drugs
- 673
- Patents
- 0
Anaxis Pharma pipeline
Portfolio lens on 200 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Anaxis Pharma drug portfolio — 200 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
abemaciclib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Cyclin-dependent kinase 4.
- Target
- Cyclin-dependent kinase 4
- Mechanism
- Cyclin-dependent kinase 6 inhibitor
-
abiraterone
Antineoplastic and immunomodulating agents (L02)Antineoplastic and immunomodulating agents (L02) compound in Anaxis Pharma's portfolio. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Steroid 5-alpha-reductase inhibitor
-
abiraterone acetate
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Steroid 17-alpha-hydroxylase/17,20 lyase.
- Target
- Steroid 17-alpha-hydroxylase/17,20 lyase
- Mechanism
- Cytochrome P450 17A1 inhibitor
-
acalabrutinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.
- Target
- Tyrosine-protein kinase BTK
- Mechanism
- Tyrosine-protein kinase BTK inhibitor
-
US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.
- Target
- Tyrosine-protein kinase BTK
- Mechanism
- Tyrosine-protein kinase BTK inhibitor
-
US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Molecular target: Carbonic anhydrase 1.
- Target
- Carbonic anhydrase 1
- Mechanism
- Carbonic anhydrase XII inhibitor
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Retinoid receptor.
- Target
- Retinoid receptor
- Mechanism
- Retinoid receptor agonist
-
US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.
- Target
- DNA polymerase catalytic subunit
- Mechanism
- Human herpesvirus 1 DNA polymerase inhibitor
-
US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.
- Target
- DNA polymerase catalytic subunit
- Mechanism
- Human herpesvirus 1 DNA polymerase inhibitor
-
adalimumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
aflibercept
Sensory organs (S01)US regulatory status: approved. Molecular target: Placenta growth factor.
- Target
- Placenta growth factor
- Mechanism
- Placenta growth factor inhibitor
-
US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved. Molecular target: Beta-2 adrenergic receptor.
- Target
- Beta-2 adrenergic receptor
- Mechanism
- Beta-2 adrenergic receptor agonist
-
US regulatory status: approved. Molecular target: Beta-2 adrenergic receptor.
- Target
- Beta-2 adrenergic receptor
- Mechanism
- Beta-2 adrenergic receptor agonist
-
US regulatory status: approved.
-
alogliptin
Alimentary tract and metabolism (A10)US regulatory status: approved. Mechanism: Dipeptidyl peptidase IV inhibitor.
- Mechanism
- Dipeptidyl peptidase IV inhibitor
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
US regulatory status: approved. Molecular target: Prostaglandin E2 receptor EP1 subtype.
- Target
- Prostaglandin E2 receptor EP1 subtype
- Mechanism
- Prostanoid EP1 receptor agonist
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha.
- Target
- Adrenergic receptor alpha
- Mechanism
- Adrenergic receptor alpha antagonist
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
amifampridine
Nervous system (N07)US regulatory status: approved. Molecular target: Voltage-gated potassium channel.
- Target
- Voltage-gated potassium channel
- Mechanism
- Voltage-gated potassium channel blocker
-
US regulatory status: approved. Mechanism: Reactive metabolite scavenging agent.
- Mechanism
- Reactive metabolite scavenging agent
-
amikacin
Antiinfectives for systemic use (J01)Antiinfectives for systemic use (J01) compound in Anaxis Pharma's portfolio.
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Dopamine receptors; D2 & D3.
- Target
- Dopamine receptors; D2 & D3
- Mechanism
- Serotonin (5-HT) receptor antagonist
-
amlodipine
Cardiovascular system (C09)Cardiovascular system (C09) compound in Anaxis Pharma's portfolio. Mechanism: Voltage-gated L-type calcium channel blocker.
- Mechanism
- Voltage-gated L-type calcium channel blocker
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
amlodipine besilate
Cardiovascular system (C09)Cardiovascular system (C09) compound in Anaxis Pharma's portfolio. Molecular target: Voltage-gated L-type calcium channel.
- Target
- Voltage-gated L-type calcium channel
- Mechanism
- Voltage-gated L-type calcium channel blocker
-
US regulatory status: approved. Molecular target: Voltage-gated L-type calcium channel.
- Target
- Voltage-gated L-type calcium channel
- Mechanism
- Voltage-gated L-type calcium channel blocker
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Norepinephrine transporter releasing agent
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Norepinephrine transporter releasing agent
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Norepinephrine transporter releasing agent
-
US regulatory status: approved. Molecular target: Ergosterol.
- Target
- Ergosterol
- Mechanism
- Ergosterol sequestering agent
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
anidulafungin
Antiinfectives for systemic use (J02)US regulatory status: approved. Molecular target: 1,3-beta-glucan synthase.
- Target
- 1,3-beta-glucan synthase
- Mechanism
- 1,3-beta-glucan synthase inhibitor
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
anti-melanoma mab fragments
Various (V09)Various (V09) compound in Anaxis Pharma's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
apalutamide
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor antagonist
-
apixaban
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: Coagulation factor X.
- Target
- Coagulation factor X
- Mechanism
- Coagulation factor X inhibitor
-
aprepitant
Alimentary tract and metabolism (A04)US regulatory status: approved. Molecular target: Substance-P receptor.
- Target
- Substance-P receptor
- Mechanism
- Neurokinin 1 receptor antagonist
-
aprocitentan
Cardiovascular system (C02)US regulatory status: approved. Molecular target: Endothelin receptor, ET-A/ET-B.
- Target
- Endothelin receptor, ET-A/ET-B
- Mechanism
- Endothelin receptor, ET-A/ET-B antagonist
-
arginine
Various (V03)Various (V03) compound in Anaxis Pharma's portfolio.
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Dopamine transporter inhibitor
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
asenapine
Nervous system (N05)US regulatory status: approved. Mechanism: Serotonin 2a (5-HT2a) receptor antagonist.
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
atezolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
US regulatory status: approved. Molecular target: Cytochrome b.
- Target
- Cytochrome b
- Mechanism
- Cytochrome b inhibitor
-
atropine
Sensory organs (S01)US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
-
atropine sulfate
Sensory organs (S01)US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
-
aumolertinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Anaxis Pharma's portfolio. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
axicabtagene ciloleucel
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Anaxis Pharma's portfolio. Molecular target: B-lymphocyte antigen CD19.
- Target
- B-lymphocyte antigen CD19
- Mechanism
- B-lymphocyte antigen CD19 binding agent
-
azacitidine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
- Target
- DNA (cytosine-5)-methyltransferase 1
- Mechanism
- DNA (cytosine-5)-methyltransferase 3A inhibitor
-
aztreonam
Antiinfectives for systemic use (J01)US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
US regulatory status: approved. Molecular target: GABA-B receptor.
- Target
- GABA-B receptor
- Mechanism
- GABA-B receptor agonist
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Histone deacetylase.
- Target
- Histone deacetylase
- Mechanism
- Histone deacetylase inhibitor
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
Development asset linked to Anaxis Pharma in public FDA and regional records. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
berotralstat
Blood and blood forming organs (B06)Blood and blood forming organs (B06) compound in Anaxis Pharma's portfolio. Mechanism: Plasma kallikrein inhibitor.
- Mechanism
- Plasma kallikrein inhibitor
-
Development asset linked to Anaxis Pharma in public FDA and regional records. Molecular target: Plasma kallikrein.
- Target
- Plasma kallikrein
- Mechanism
- Plasma kallikrein inhibitor
-
bevacizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor antagonist
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
bimekizumab
Antineoplastic and immunomodulating agents (L04)Antineoplastic and immunomodulating agents (L04) compound in Anaxis Pharma's portfolio. Molecular target: Interleukin-17A.
- Target
- Interleukin-17A
- Mechanism
- Interleukin-17F inhibitor
-
US regulatory status: approved. Molecular target: Interleukin-17A.
- Target
- Interleukin-17A
- Mechanism
- Interleukin 17A inhibitor
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
bivalirudin
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: Prothrombin.
- Target
- Prothrombin
- Mechanism
- Thrombin inhibitor
-
bortezomib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: 26S proteasome.
- Target
- 26S proteasome
- Mechanism
- 26S proteosome inhibitor
-
bosutinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Anaxis Pharma's portfolio. Molecular target: Tyrosine-protein kinase ABL1.
- Target
- Tyrosine-protein kinase ABL1
- Mechanism
- Tyrosine-protein kinase ABL inhibitor
-
brentuximab vedotin
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
brexucabtagene autoleucel
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Anaxis Pharma's portfolio. Molecular target: B-lymphocyte antigen CD19.
- Target
- B-lymphocyte antigen CD19
- Mechanism
- B-lymphocyte antigen CD19 binding agent
-
brigatinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: ALK tyrosine kinase receptor.
- Target
- ALK tyrosine kinase receptor
- Mechanism
- ALK tyrosine kinase receptor inhibitor
-
US regulatory status: approved. Molecular target: DNA polymerase.
- Target
- DNA polymerase
- Mechanism
- DNA polymerase inhibitor
-
brivaracetam
Nervous system (N03)US regulatory status: approved. Molecular target: Synaptic vesicle glycoprotein 2A.
- Target
- Synaptic vesicle glycoprotein 2A
- Mechanism
- Synaptic vesicle glycoprotein 2A modulator
-
Development asset linked to Anaxis Pharma in public FDA and regional records. Molecular target: Gamma-aminobutyric acid receptor subunit alpha-2.
- Target
- Gamma-aminobutyric acid receptor subunit alpha-2
- Mechanism
- GABA receptor alpha-2 subunit positive allosteric modulator
-
Development asset linked to Anaxis Pharma in public FDA and regional records. Mechanism: Dopamine transporter inhibitor.
- Mechanism
- Dopamine transporter inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Dopamine transporter inhibitor
-
busulfan
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
cabazitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
cabozantinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Mechanism: Hepatocyte growth factor receptor inhibitor.
- Mechanism
- Hepatocyte growth factor receptor inhibitor
-
caffeine
Nervous system (N06)US regulatory status: approved. Molecular target: Adenosine receptor.
- Target
- Adenosine receptor
- Mechanism
- Adenosine receptor antagonist
-
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
Development asset linked to Anaxis Pharma in public FDA and regional records. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
US regulatory status: approved.
-
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
-
US regulatory status: approved.
-
cannabidiol
Nervous system (N03)US regulatory status: approved. Molecular target: Cannabinoid receptor 1.
- Target
- Cannabinoid receptor 1
- Mechanism
- Cannabinoid CB1 receptor negative allosteric modulator
-
capecitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
capsaicin
Nervous system (N01)US regulatory status: approved. Molecular target: Transient receptor potential cation channel subfamily V member 1.
- Target
- Transient receptor potential cation channel subfamily V member 1
- Mechanism
- Vanilloid receptor opener
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Angiotensin-converting enzyme.
- Target
- Angiotensin-converting enzyme
- Mechanism
- Angiotensin-converting enzyme inhibitor
-
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
carfilzomib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: 26S proteasome.
- Target
- 26S proteasome
- Mechanism
- 26S proteosome inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha-1.
- Target
- Adrenergic receptor alpha-1
- Mechanism
- Adrenergic receptor beta antagonist
-
caspofungin
Antiinfectives for systemic use (J02)Antiinfectives for systemic use (J02) compound in Anaxis Pharma's portfolio.
-
cefepime
Antiinfectives for systemic use (J01)Antiinfectives for systemic use (J01) compound in Anaxis Pharma's portfolio.
-
ceftobiprole
Antiinfectives for systemic use (J01)Antiinfectives for systemic use (J01) compound in Anaxis Pharma's portfolio. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
US regulatory status: approved.
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
cemiplimab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Anaxis Pharma's portfolio. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
cetuximab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
US regulatory status: approved. Molecular target: Cell membrane.
- Target
- Cell membrane
- Mechanism
- Cell membrane inhibitor
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
chlormethine
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Anaxis Pharma's portfolio. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: Solute carrier family 12 member 3.
- Target
- Solute carrier family 12 member 3
- Mechanism
- Thiazide-sensitive sodium-chloride cotransporter inhibitor
-
US regulatory status: approved. Molecular target: Solute carrier family 12 member 3.
- Target
- Solute carrier family 12 member 3
- Mechanism
- Thiazide-sensitive sodium-chloride cotransporter inhibitor
-
cholic acid
Alimentary tract and metabolism (A05)US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
cidofovir
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.
- Target
- DNA polymerase catalytic subunit
- Mechanism
- Human herpesvirus 1 DNA polymerase inhibitor
-
US regulatory status: approved. Molecular target: Histamine H2 receptor.
- Target
- Histamine H2 receptor
- Mechanism
- Histamine H2 receptor antagonist
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Anaxis Pharma in public FDA and regional records. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
cladribine
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
US regulatory status: approved. Molecular target: D(2) dopamine receptor.
- Target
- D(2) dopamine receptor
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
Development asset linked to Anaxis Pharma in public FDA and regional records. Mechanism: Opioid receptors; mu/kappa/delta agonist.
- Mechanism
- Opioid receptors; mu/kappa/delta agonist
-
US regulatory status: approved. Molecular target: Opioid receptors; mu/kappa/delta.
- Target
- Opioid receptors; mu/kappa/delta
- Mechanism
- Opioid receptors; mu/kappa/delta agonist
-
colchicine
Musculo-skeletal system (M04)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Anoctamin-1.
- Target
- Anoctamin-1
- Mechanism
- Cystic fibrosis transmembrane conductance regulator inhibitor
-
US regulatory status: approved. Mechanism: Supplement.
- Mechanism
- Supplement
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
cytarabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
dabrafenib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Anaxis Pharma's portfolio. Mechanism: Serine/threonine-protein kinase B-raf inhibitor.
- Mechanism
- Serine/threonine-protein kinase B-raf inhibitor
-
danicopan
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Complement factor D.
- Target
- Complement factor D
- Mechanism
- Complement factor D inhibitor
-
Development asset linked to Anaxis Pharma in public FDA and regional records. Mechanism: Ryanodine receptor 3 antagonist.
- Mechanism
- Ryanodine receptor 3 antagonist
-
US regulatory status: approved. Molecular target: Ryanodine receptor 1.
- Target
- Ryanodine receptor 1
- Mechanism
- Ryanodine receptor 3 antagonist
-
daratumumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.
- Target
- ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
- Mechanism
- Lymphocyte differentiation antigen CD38 inhibitor
-
daridorexant
Nervous system (N05)Nervous system (N05) compound in Anaxis Pharma's portfolio. Molecular target: Orexin receptor.
- Target
- Orexin receptor
- Mechanism
- Orexin receptor antagonist
-
dasatinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Bcr/Abl fusion protein.
- Target
- Bcr/Abl fusion protein
- Mechanism
- SRC inhibitor
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Vasopressin receptor.
- Target
- Vasopressin receptor
- Mechanism
- Vasopressin receptor agonist
-
US regulatory status: approved. Molecular target: Progesterone receptor.
- Target
- Progesterone receptor
- Mechanism
- Progesterone receptor agonist
-
US regulatory status: approved. Molecular target: Mineralocorticoid receptor.
- Target
- Mineralocorticoid receptor
- Mechanism
- Mineralocorticoid receptor agonist
-
deucravacitinib
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Non-receptor tyrosine-protein kinase TYK2.
- Target
- Non-receptor tyrosine-protein kinase TYK2
- Mechanism
- Tyrosine-protein kinase TYK2 negative allosteric modulator
-
dexamethasone
Systemic hormonal preparations (H02)US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
dexamethasone phosphate
Systemic hormonal preparations (H02)Systemic hormonal preparations (H02) compound in Anaxis Pharma's portfolio.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Anaxis Pharma in public FDA and regional records. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Dopamine transporter releasing agent
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Norepinephrine transporter releasing agent
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Dopamine transporter releasing agent
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Norepinephrine transporter releasing agent
-
US regulatory status: approved.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
US regulatory status: approved. Molecular target: Sodium/potassium-transporting ATPase.
- Target
- Sodium/potassium-transporting ATPase
- Mechanism
- Sodium/potassium-transporting ATPase inhibitor
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
Development asset linked to Anaxis Pharma in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
Development asset linked to Anaxis Pharma in public FDA and regional records. Mechanism: Sodium channel alpha subunit blocker.
- Mechanism
- Sodium channel alpha subunit blocker
-
Development asset linked to Anaxis Pharma in public FDA and regional records. Mechanism: Surfactant laxative.
- Mechanism
- Surfactant laxative
-
Development asset linked to Anaxis Pharma in public FDA and regional records.
-
Development asset linked to Anaxis Pharma in public FDA and regional records. Mechanism: Beta-1 adrenergic receptor agonist.
- Mechanism
- Beta-1 adrenergic receptor agonist
-
Development asset linked to Anaxis Pharma in public FDA and regional records.